Mario Venditti - Infectious Diseases

Author Information

Mario Venditti is a distinguished researcher affiliated with the Department of Public Health and Infectious Diseases at Policlinico Umberto I, "Sapienza" University of Rome. His work is primarily focused on infectious diseases, with a particular emphasis on bacterial infections and the treatment of multidrug-resistant organisms. His contributions to the field are recognized for their impact and depth, particularly in the context of clinical settings and treatment methodologies.

Research Contributions

Mario Venditti has made significant contributions to the study and treatment of infectious diseases. His research spans a variety of topics, including the compassionate use of novel antibiotics like meropenem/vaborbactam for treating infections caused by KPC-producing Klebsiella pneumoniae, and strategies for managing SARS-CoV-2 infections, especially in patients with compromised immune systems. He has also explored the use of convalescent plasma in hematological patients and developed predictive scoring systems for thrombotic events in COVID-19 patients. His work often involves multicentre studies and the development of combination therapies to combat resistant strains of bacteria.

Aliases

Mario Venditti is also known by the aliases M Venditti and M. Venditti. These variations are used interchangeably in academic publications and professional settings.

Publication and Citation Metrics

Metric	Value
Total Citation Count	11,990
h-index	58
Total Number of Papers	400

Publications:

Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study

DOI: 10.1093/jacamr/dlac022

Year: 2022

Convalescent plasma for haematological patients with SARS-CoV-2 pneumonia and severe depletion of B-cell lymphocytes following anti-CD20 therapy: a single-centre experience and review of the literature.

DOI:

Year: 2022

THE ADA (AGE-D-DIMER-ALBUMIN) SCORE TO PREDICT THROMBOSIS IN SARS-CoV-2.

DOI: 10.1055/a-1788-7592

Year: 2022

Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study

DOI: 10.1007/s40121-021-00585-6

Year: 2022

Role of dalbavancin as combination therapy: evidences from the literature and clinical scenarios.

DOI: 10.1080/14787210.2022.2060820

Year: 2022

Interplay between Klebsiella pneumoniae producing KPC-31 and KPC-3 under treatment with high dosage meropenem: a case report

DOI: 10.1007/s10096-021-04388-y

Year: 2022

Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections in Patients with Liver Cirrhosis

DOI: 10.1016/j.jceh.2022.04.016

Year: 2022

High Activity of N-Acetylcysteine in Combination with Beta-Lactams against Carbapenem-Resistant Klebsiella pneumoniae and Acinetobacter baumannii

DOI: 10.3390/antibiotics11020225

Year: 2022

CURB-65 plus hypoalbuminemia: a new score system for prediction of the in-hospital mortality risk in patients with SARS-CoV-2 pneumonia.

DOI: 10.53854/liim-2903-12

Year: 2021

Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit

DOI: 10.1007/s15010-021-01643-4

Year: 2021

What are Structural Proteins?

How is Treatment Monitored?

What are Genomic and Proteomic Studies?

How is Dengue Transmitted?

How Do Serological Tests Work?

What is the impact of climate change on infectious diseases?

How Does Co-Infection Occur?

What are the guidelines for food safety?

What is the CDCâs Role in Vaccine Development?

How Can Yellow Fever Be Prevented?

Partnered Content Networks

Relevant Topics